Sevacizumab

Drug Profile

Sevacizumab

Alternative Names: Anti-VEGF monoclonal antibody - Apexigen; APX-003; BD-0801; EP-10030; SIM-BD-0801; TK 001

Latest Information Update: 12 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Epitomics
  • Developer Apexigen; Jiangsu T-mab BioPharma; Simcere Pharmaceutical Group
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Solid tumours
  • Phase I Wet age-related macular degeneration
  • No development reported Cancer

Most Recent Events

  • 01 Jun 2018 Adverse events and efficacy data from a phase Ib trial in Colorectal cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 01 Sep 2017 Jiangsu T-Mab Biopharma initiates enrolment in a phase I trial for Wet age-related macular degeneration (In adults, In the elderly) in China (Intravitreous, Injection) (NCT03021785)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top